ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $287.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 12.14% year-over-year to $287.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 16.41% YoY), and the FY2025 full-year result was $327.7 million, down 6.69% from the prior year.
• Liabilities and Shareholders Equity declined to $287.6 million in Q1 2026, from $327.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $372.8 million in Q3 2025 to a low of $217.6 million in Q3 2024.
• A 5-year average of $283.4 million and a median of $281.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 358.02% in 2022, while the deepest fall reached 23.12% in 2022.
• Tracing SPRY's Liabilities and Shareholders Equity over 5 years: stood at $281.4 million in 2022, then slipped by 17.14% to $233.2 million in 2023, then soared by 50.59% to $351.2 million in 2024, then fell by 6.69% to $327.7 million in 2025, then dropped by 12.23% to $287.6 million in 2026.
• Business Quant data shows SPRY's Liabilities and Shareholders Equity at $287.6 million in Q1 2026, $327.7 million in Q4 2025, and $372.8 million in Q3 2025.